Latest From BeiGene Ltd.
A report from a short-seller firm has put Beijing-based biotech bellwether BeiGene in an unwanted spotlight, prompting management to defend its record.
Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
Drug Discovery Tools
- Drug Discovery Tools
- In Vitro Diagnostics
- Therapeutic Areas
- BeiGene (Beijing) Co. Ltd.
- Parent & Subsidiaries
- BeiGene Ltd.
- Senior Management
John V Oyler, CEO
Howard Liang, PhD, CFO & Chief Strategy Officer
- Contact Info
Phone: 10 58958000
No. 30 Science Park Rd. Zhong-Guan-Cun
Life Science Pk
Changping District, 102206
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.